SKN | Therapeutics Sector Under the Microscope: How Moderna Stacks Up Against Peers After Q4
Financial Performance The therapeutics sector is undergoing a significant recalibration as companies report fourth-quarter results in a post-pandemic environment. Moderna (NASDAQ:MRNA), once a standout performer due to vaccine-driven revenues, now faces a more complex landscape defined by normalization, pipeline development, and evolving investor expectations. Across the sector, companies are being reassessed based on long-term growth potential […]